Volume 61, Issue 3, Pages (March 2012)

Slides:



Advertisements
Similar presentations
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Advertisements

Volume 72, Issue 3, Pages (September 2017)
Volume 56, Issue 5, Pages (November 2009)
Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series 
Volume 22, Issue 5, Pages (October 2013)
Volume 62, Issue 3, Pages (September 2012)
Volume 50, Issue 3, Pages (September 2006)
Volume 70, Issue 4, Pages (October 2016)
The PSA Era is not Over for Prostate Cancer
Volume 67, Issue 4, Pages (April 2015)
Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
RELAZIONE TRA “STAGE MIGRATION” E
Volume 59, Issue 1, Pages (January 2011)
Volume 62, Issue 4, Pages (October 2012)
Testosterone Therapy in Men With Prostate Cancer
Volume 70, Issue 4, Pages (October 2016)
Prostate Cancer: Highlights from 2006
Volume 61, Issue 5, Pages (May 2012)
Volume 51, Issue 6, Pages (June 2007)
Volume 73, Issue 5, Pages (May 2018)
Volume 69, Issue 1, Pages (January 2016)
Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database 
Volume 70, Issue 5, Pages (November 2016)
Volume 54, Issue 4, Pages (October 2008)
Volume 63, Issue 6, Pages (June 2013)
Volume 56, Issue 3, Pages (September 2009)
Volume 53, Issue 5, Pages (May 2008)
Volume 68, Issue 5, Pages (November 2015)
Nomograms for Bladder Cancer
Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage
Volume 67, Issue 2, Pages (February 2015)
Volume 60, Issue 5, Pages (November 2011)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
European Urology Oncology
Volume 63, Issue 6, Pages (June 2013)
The PSA Era is not Over for Prostate Cancer
Volume 48, Issue 6, Pages (December 2005)
Volume 66, Issue 5, Pages (November 2014)
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 70, Issue 6, Pages (December 2016)
Volume 45, Issue 5, Pages (May 2004)
Validation of Preoperative Nomograms Predicting Lymph Node Involvement in Prostate Cancer: A Bi-institutional Study  Alexander I. Hinev, Vesselin I. Hadjiev,
Volume 70, Issue 6, Pages (December 2016)
Volume 54, Issue 3, Pages (September 2008)
Volume 66, Issue 2, Pages (August 2014)
Volume 59, Issue 1, Pages (January 2011)
Volume 60, Issue 6, Pages (December 2011)
Prostate Cancer Nomograms: An Update
Testicular Cancer Variations in Time and Space in Europe
Volume 49, Issue 4, Pages (April 2006)
Volume 66, Issue 6, Pages (December 2014)
Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of.
Volume 54, Issue 4, Pages (October 2008)
PSA Levels and the Probability of Prostate Cancer on Biopsy
Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer  Felix Preisser, Michele Marchioni, Sebastiano.
European Urology Oncology
European Urology is “Your” Journal
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Volume 50, Issue 5, Pages (November 2006)
Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.
Mary K. Samplaski, M. D. , Changhong Yu, M. S. , Michael W. Kattan, Ph
Volume 54, Issue 1, Pages (July 2008)
The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review  Fritz Schröder,
Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.
Volume 52, Issue 2, Pages (August 2007)
Fernando P. Secin, Fernando J. Bianco, Nicholas T
European Urology Oncology
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
Presentation transcript:

Volume 61, Issue 3, Pages 480-487 (March 2012) Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores  Alberto Briganti, Alessandro Larcher, Firas Abdollah, Umberto Capitanio, Andrea Gallina, Nazareno Suardi, Marco Bianchi, Maxine Sun, Massimo Freschi, Andrea Salonia, Pierre I. Karakiewicz, Patrizio Rigatti, Francesco Montorsi  European Urology  Volume 61, Issue 3, Pages 480-487 (March 2012) DOI: 10.1016/j.eururo.2011.10.044 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Nomogram predicting the probability of lymph nodes invasion (LNI) in patients undergoing extended pelvic lymphadenectomy based on pretreatment prostate-specific antigen (PSA), clinical stage, primary and secondary biopsy Gleason score, and percentage of positive cores. Instructions: Locate the patient's pretreatment PSA on the PSA axis. Draw a line straight upward to the point axis to determine how many points toward the probability of positive lymph nodes the patient receives for his PSA value. Repeat the process for each additional variable. Sum the points for each of the predictors. Locate the final sum on the total point axis. Draw a line straight down to find the patient's probability of having LNI. European Urology 2012 61, 480-487DOI: (10.1016/j.eururo.2011.10.044) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Nomogram calibration plot. Dotted line indicates location of the ideal nomogram, in which predicted and actual probabilities are identical. Broken line indicates actual nomogram performance. Expected performance on future data is represented through the solid line. Calibration was tested for both models, with or without percentage of positive cores (PCC) (full and base model, respectively). European Urology 2012 61, 480-487DOI: (10.1016/j.eururo.2011.10.044) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 3 Decision curve analyses demonstrating the net benefit associated with the use of the nomogram with (model 2: full model) or without (model 1: base model) the inclusion of the percentage of positive cores as covariate. Net benefit can be interpreted as the proportion of all patients who have lymph node metastases and are recommended for extended pelvic lymph node dissection if no patients with negative lymph nodes were treated. European Urology 2012 61, 480-487DOI: (10.1016/j.eururo.2011.10.044) Copyright © 2011 European Association of Urology Terms and Conditions